BSE filing, NSE: KPEL. Summary written from the filing by ALFA Finder's alert engine.
K P Energy Ltd: key numbers
- Share price
- ₹160.84
- Market cap
- ₹1,090 Cr
- Revenue (annual)
- ₹1,497 Cr
- Net profit (annual)
- ₹181.4 Cr
- P/E (TTM)
- 6.0×Sector 21.4×
- Promoter holding
- 45.31%+0.00% QoQ
- FII holding
- 0.55%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from K P Energy Ltd
All →K P Energy Other Announcement
K.P. Energy Ltd has submitted its shareholding pattern for the quarter ended September 30, 2026, in compliance with SEBI regulatory requirements.
K P Energy Investor Presentation: Key Takeaways
KP Group Investor Day presentation highlighting KP 3.0 strategy. Focuses on scaling IPP, EPC, and BESS platforms to 10GWp/10GWh targets by FY32.
K P Energy Management Change
K.P. Energy Limited appointed Prof. Sunil Kumar Maheshwari as Executive Director and M S K C & Associates LLP as Statutory Auditors, approved at the AGM.
K P Energy Annual General Meeting
K.P. Energy Limited held its 17th Annual General Meeting on September 29, 2026. Shareholders transacted ordinary and special resolutions regarding financial statements, dividends, and director appointments.
K P Energy Bags ₹16 Cr Order from Emmvee Energy Private Limited
K.P. Energy received an LOI from Emmvee Energy for a 42 MW wind-solar hybrid captive project in Karnataka. Estimated equity investment is ₹16 Crore at a PPA tariff of ₹3.61/kWh.
- Value
- ₹16.00 Cr
- From
- Emmvee Energy Private Limited
- wind-solar hybrid power capacity
- 42.0 MW
K P Energy Bags New Order from Emmvee Energy Private Limited
K.P. Energy Limited received a Letter of Intent from Emmvee Energy Private Limited for a 42 MW wind-solar hybrid power project in Karnataka.
- From
- Emmvee Energy Private Limited
- Execution
- to be mutually agreed upon
- Wind-Solar Hybrid Power Project
- 42.0 MW
Other regulatory approval announcements
All →Gland Pharma Regulatory Approval
Gland Pharma received USFDA approval for Methylprednisolone Acetate Injectable Suspension USP in multiple vial formats. The product is bioequivalent to Pfizer's Depo-Medrol in a ~$214M US market.
City Union Bank Regulatory Approval
City Union Bank disclosed RBI approval for appointing Shri Sankaran G as Executive Director (Whole-time Director) for three years. The board appointment and formal disclosures will follow later.
- Execution
- Three years from the date of taking charge
Lupin Regulatory Approval
Lupin received US FDA approval for its generic Amifampridine Tablets 10 mg ANDA. As a first-to-file applicant, it is eligible for 180-day shared generic exclusivity.
Som Distilleries & Breweries Regulatory Approval
Som Distilleries received manufacturing licences for its Bhopal plant from the Madhya Pradesh Excise Department, plus product label and rate approvals. Manufacturing and sales are expected to resume soon.
AGI Infra Regulatory Approval
Agi Infra received RERA registration PBRERA-SAS80-PR1452-102026 from Punjab RERA for its Utopia by AGI group housing project in New Chandigarh. The registration is valid until 30 March 2031.
- Execution
- Valid up to March 30, 2031
360 One Wam Regulatory Approval
360 ONE Distribution Services' IFSC branch, a subsidiary of 360 ONE WAM, received an IFSCA Certificate of Registration to act as broker dealer, clearing member, depository participant, research entity and distributor. This is a regulatory licence authorising new activities in the IFSC.